A detailed history of Invesco Ltd. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 115,551 shares of RXRX stock, worth $714,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares
115,551
Previous 108,267 6.73%
Holding current value
$714,105
Previous $812,000 6.28%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.92 - $8.6 $43,121 - $62,642
7,284 Added 6.73%
115,551 $761,000
Q2 2024

Aug 13, 2024

BUY
$7.35 - $10.05 $71,317 - $97,515
9,703 Added 9.84%
108,267 $812,000
Q1 2024

May 14, 2024

SELL
$9.13 - $15.52 $203,799 - $346,437
-22,322 Reduced 18.47%
98,564 $982,000
Q4 2023

Feb 12, 2024

BUY
$5.09 - $10.79 $70,221 - $148,858
13,796 Added 12.88%
120,886 $1.19 Million
Q3 2023

Nov 13, 2023

BUY
$6.59 - $15.86 $3,822 - $9,198
580 Added 0.54%
107,090 $819,000
Q2 2023

Aug 11, 2023

SELL
$4.56 - $9.94 $57,934 - $126,287
-12,705 Reduced 10.66%
106,510 $795,000
Q1 2023

May 12, 2023

BUY
$6.42 - $9.64 $478,899 - $719,095
74,595 Added 167.18%
119,215 $795,000
Q4 2022

Feb 13, 2023

SELL
$7.16 - $12.7 $2,377 - $4,216
-332 Reduced 0.74%
44,620 $344,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $5,238 - $9,098
669 Added 1.51%
44,952 $478,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.26 $1,764 - $3,241
-350 Reduced 0.78%
44,283 $361,000
Q1 2022

May 16, 2022

BUY
$6.16 - $18.03 $7,145 - $20,914
1,160 Added 2.67%
44,633 $320,000
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $701,654 - $950,319
43,473 New
43,473 $745,000
Q3 2021

Nov 15, 2021

SELL
$19.03 - $41.33 $106,796 - $231,943
-5,612 Closed
0 $0
Q2 2021

Aug 17, 2021

BUY
$18.0 - $37.42 $101,016 - $210,001
5,612 New
5,612 $205,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.